Cochrane Abstracts
Bifeprunox versus placebo for schizophrenia
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Bifeprunox Versus Placebo for Schizophrenia." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434689/all/Bifeprunox_versus_placebo_for_schizophrenia.
Bifeprunox versus placebo for schizophrenia. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434689/all/Bifeprunox_versus_placebo_for_schizophrenia. Accessed November 25, 2024.
Bifeprunox versus placebo for schizophrenia. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434689/all/Bifeprunox_versus_placebo_for_schizophrenia
Bifeprunox Versus Placebo for Schizophrenia [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 November 25]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434689/all/Bifeprunox_versus_placebo_for_schizophrenia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Bifeprunox versus placebo for schizophrenia
ID - 434689
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434689/all/Bifeprunox_versus_placebo_for_schizophrenia
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
